notizia | Italian Medicines Agency

notizia | Italian Medicines Agency Aifa toggle bar Search Search keywords The Agency The Agency Mission and values Organisation Scientific and Economic Committee for Medicines Support and Coordination Secretariats and Advisory Committees International Collaborations EU Projects Legislation Forms Competition notices Resolutions Tenders and contracts Quality assurance Guarantee Committee Atti di notifica Associazioni dei pazienti AIFA Incontra Contacts Certified email COVID-19 COVID-19 Communications about COVID-19 COVID-19 Vaccines Medicines usable for treatment of COVID-19 disease Use of monoclonal antibodies for COVID-19 Use of antivirals for COVID-19 Monitoring of medicinal products used during the COVID-19 epidemic Clinical Trials - COVID-19 Compassionate Use Programs - COVID-19 Access to medicinal products Access to medicinal products Early access and off-label use Authorisation of medicinal products Medicine shortages Antibiotic medicinal products Biological medicinal products Vaccines Blood derivatives Generic medicinal products Biosimilar medicinal products Orphan medicinal products Advanced therapies Homeopathic medicinal products Allergens Medicinali di origine vegetale Ancillary medicinal substances incorporated in medical devices Safety of medicinal products Safety of medicinal products Pharmacovigilance National Pharmacovigilance Network Adverse Reactions to medicinal products Persons in charge of Pharmacovigilance European Eudravigilance System Accesso alle segnalazioni - ADRreports Regional pharmacovigilance funds Segnali di sicurezza Risk management measures Medicinal products subject to additional monitoring Quality and Inspections Quality and Inspections Quality defects Inspections and authorisations Qualified person Fight of pharmaceutical crime Research and Clinical trials Research and Clinical trials Clinical trials concerning medicinal products EU Regulation on Clinical trials National Observatory on Clinical Trials Registro Studi Osservazionali Comitati Etici Nazionali (CEN) Ethics Committees Coordination Centre Independent clinical research Mappa dei centri di Sperimentazione Clinica Pricing and reimbursement Pricing and reimbursement Negotiation and reimbursement Economic evaluations Monitoring Registers AIFA Notes Lists of Class A and Class H medicinal products Innovative medicinal products Transparency Lists Consumption and pharmaceutical expenditure Consumption and pharmaceutical expenditure The Medicines Utilization Monitoring Centre (OsMed) Governance of pharmaceutical expenditure Monitoring pharmaceutical expenditure Innovation and planning Innovation and planning Innovation and scientific advice Horizon scanning Information and communication Information and communication FarmaciLine Medical and scientific information FAQ Publications Communication campaigns Eventi AIFA Scientific Seminars Press releases Dossier AIFA Mobile APP AIFA APP Firstline AIFA - Antibiotici ABC della Ricerca Clinica Presentations and speeches Public consultations and documents Documents shared with scientific communities Calendario eventi Archivio AIFA data AIFA data OsMed Data Open Data Companies Section Companies Section Requests for authorisation of conferences and meetings Payment of fees and annual duties MA Electronic invoicing Application for reimbursement and pricing Access information Notifica concessionari di vendita Comunicazione prima commercializzazione Open governance Open governance Disposizioni Generali Organizzazione Consulenti e collaboratori Personale Bandi di Concorso Performance Enti controllati Attività e procedimenti Provvedimenti Bandi di gara e contratti Sovvenzioni, contributi, sussidi, vantaggi economici Bilanci Beni immobili e gestione patrimonio Controlli e rilievi sull'Amministrazione Servizi Erogati Pagamenti dell'Amministrazione Opere pubbliche Pianificazione e governo del territorio Informazioni ambientali Interventi straordinari di emergenza Altri Contenuti From one-size-fits-all treatments to personalised care: the revolution in precision medicine - From one-size-fits-all treatments to personalised care: the revolution in precision medicine Asset Publisher From one-size-fits-all treatments to personalised care: the revolution in precision medicine The new AIFA report examines the clinical and economic impact of targeted therapies and prescriptomics Medicine is undergoing a profound transformation: we are moving away from a standardised approach based on the ‘average patient’ towards a person-centred model capable of tailoring diagnoses and treatments to the genetic, clinical and environmental characteristics of each individual. This is the paradigm of precision medicine, which forms the focus of the AIFA report, analysing the impact of this evolution on both clinical practice and sustainability of the National Health Service. Over the last twenty years, advances in genomics and digital technologies have highlighted a limitation of traditional medicine: patients with the same condition can respond very differently to the same treatment. This has given rise to the need for a more targeted approach, capable of identifying the most effective treatment for each individual, thereby avoiding unnecessary or potentially harmful therapies. In clinical practice, this model is implemented through the use of innovative tools: genomics and pharmacogenomics enable the analysis of DNA to identify variants that influence the response to drugs; transcriptomics, proteomics and metabolomics allow us to observe the biological activity of cellular systems; epigenetics studies changes linked to the environment and lifestyle; whilst bioinformatics and artificial intelligence integrate large amounts of data to support clinical decision-making. Thanks to these technologies, it is possible to predict drug responses, identify patients at risk of side effects and select targeted treatments based on the molecular characteristics of the disease. “Precision medicine is not a luxury for the few, but a right for everyone,” emphasises AIFA President Robert Nisticò . “It is the most ethical and effective way to treat patients, because it avoids unnecessary treatments and truly puts the individual at the centre.” This shift is particularly significant in Italy, one of the countries with the highest life expectancy in the world. An ageing population leads to an increase in chronic conditions and so-called polypharmacy. Living with multiple conditions means having to take more medicines and it represents one of the main clinical and social challenges of our time: 68% of those over 65 are prescribed at least five different medicines, and 28.5% take ten or more. This situation exponentially increases the risk of drug interactions, treatment errors and adverse reactions, but it also has a significant social impact: it reduces the independence of older people, complicates the lives of carers and generates direct and indirect costs for the healthcare system. The so-called ‘cascading prescribing’ is a real risk: a drug is prescribed to treat a side effect caused by another, triggering a vicious circle that leads the patient to take an increasing number of medicines. “We can no longer allow polypharmacy to become a burden for the elderly ,” Nisticò points out. “The challenge is to prescribe better, not more, by using genetic and clinical information to avoid unnecessary risks.” This is where prescriptomics comes in, a discipline that applies the principles of precision medicine to the management of drug therapies, with the aim of optimising prescriptions and reducing drug interactions. “Prescriptomics is the bridge between genetic knowledge and everyday clinical practice,” adds Nisticò. “It means moving beyond trial-and-error medicine and offering safer treatments, especially to the most vulnerable patients.” One area where this revolution is already a reality is oncology. For decades, chemotherapy has been the mainstay of cancer treatment, indiscriminately targeting both cancerous and healthy cells, with significant side effects. Targeted therapies, on the other hand, recognise and block specific molecular mechanisms in cancer cells, making them more selective and generally better tolerated. The main categories of targeted cancer drugs include: Tyrosine kinase inhibitors (TKIs): these work by blocking enzymes that are essential for tumour growth. They have revolutionised the treatment of certain leukaemias and are used in lung and gastrointestinal cancers. Monoclonal antibodies: molecules designed to recognise specific targets on cancer cells. Anti-HER2 drugs, for example, have changed the prognosis for HER2-positive breast cancer. Immunotherapies: drugs that activate the immune system against the tumour, such as immune checkpoint inhibitors, now used in numerous advanced cancers. Antibody-drug conjugates (ADCs): these combine monoclonal antibodies with cytotoxic agents, delivering the drug directly to tumour cells and reducing the impact on healthy tissue. Therapeutic vaccines: still in development, these aim to train the immune system to recognise and selectively target tumour cells. Biomarkers play a central role: in order to select the most effective treatment, knowing the tumour location is not enough but it is necessary to analyse its molecular profile. Mutations in genes such as EGFR, ALK or ROS1 guide treatment choices, shifting the focus from the tumour’s anatomical location to the disease’s ‘genetic code’. Precision therapies have significantly improved the prognosis for many cancers, but they still have significant limitations: the development of resistance, high costs and uneven access to molecular testing. "In oncology, precision medicine is already a reality, but it requires a paradigm shift,” Nisticò observes. “We must move from an organ-based approach to one based on the molecular characteristics of the disease.” Looking to the future, AIFA report highlights the growing role of artificial intelligence and bioinformatics, which will enable the development of increasingly accurate predictive models and the integration of clinical, genetic and environmental data. Among the most innovative developments is the pharmacogenomic passport, a genetic identity card for patients that could accompany them throughout their lives. “The pharmacogenomic passport represents a real prospect for improving the safety and efficacy of treatments,” Nisticò concludes. “It is a challenge that requires governance, fairness and accountability in the use of data.” Precision medicine therefore represents not only a scientific advancement, but a structural and cultural shift that affects the entire healthcare system. The challenge is to make it accessible, equitable and sustainable, transforming innovation into a tangible benefit for all citizens. The path forward is clear: moving beyond the ‘one-size-fits-all’ model in order to build a healthcare system that is more effective, more sustainable and truly tailored to each individual. Published on: 17 April 2026 Asset Publisher Related documents Press release No. 17/2026 [0.57 Mb] [PDF] > Dossier AIFA - Dalle terapie a taglia unica alle cure su misura - La rivoluzione della medicina di precisione [1.01 Mb] [PDF] > Asset Publisher Information and communication FarmaciLine Medical and scientific information FAQ Publications Communication campaigns Eventi AIFA Scientific Seminars Press releases Dossier AIFA Mobile APP AIFA APP Firstline AIFA - Antibiotici ABC della Ricerca Clinica Presentations and speeches Public consultations and documents Documents shared with scientific communities Calendario eventi Archivio Share Nested Applications Highlights 08/04/2026 - Regulations for AIFA Incontra and AIFA Ascolta Approved 02/04/2026 - AIFA executives on institutional mission to Japan for the first time ALL NEWS ALL NEWS News 21/04/2026 Medicine Use: 2024 Regional Reports Now Available Online 15/04/2026 AIFA updates the Transparency Lists 13/04/2026 Medicine Shortage Communication on Endoxan (ciclofosfamide) All news Galleria Nested Applications Press From one-size-fits-all treatments to personalised care: the revolution in precision medicine All press releases Last tweets 📢 #AIFA comunica il calendario degli incontri nell’ambito delle iniziative dedicate al dialogo e al... Vai al post → 🔬 AIFA pubblica il dossier “Dalle terapie a taglia unica alle cure su misura: la rivoluzione della ... Vai al post → 🎙️ “Immagino un futuro in cui ciascuno di noi abbia un vero e proprio passaporto farmacogenetico, m... Vai al post → 💊 Quasi 4 cittadini su 10 hanno ricevuto almeno una prescrizione di #antibiotici nel 2024, con una ... Vai al post → ⚠️ Attenzione alle false cure miracolose Negli ultimi tempi si sta diffondendo un business pericol... Vai al post → #AIFA promuove l’ascolto e la trasparenza Approvati i Regolamenti di “AIFA Ascolta” e “AIFA Incontr... Vai al post → Go to Twitter profile Go to Twitter profile aifa_ufficiale Multimedia Medicina di precisione e appropriatezza prescrittiva Go to YouTube channel Cookie Bar Footer The agency Home Page FarmaciLine User participation and satisfaction Citizens' access Modulistica Open governance Acts of notification Legal notification TrovaNormeFarmaco Competition notices Tenders and contracts Contacts Via del Tritone, 181 00187 Roma Contacts Certified e-mail (PEC) contacts VAT number: 08703841000 Tax code: 97345810580 IPA AIFA code: aifa_rm IPA UCB code: UFE1TR FOLLOW US ON label.button.spotify Bluesky FEED RSS Feed Rss Cookie management Sezione Link Utili Legal notice Social Media Policy Dichiarazione di accessibilità Web accessibility Website statistics Online services go to beginning of content